Background: Helicobacter pylori (Hp) is a Gram-negative bacteria and the cause of most of the chronic gastric infections and its prevalence is above 50% worldwide. This infection is a well-known risk factor to gastric MALT lymphoma but also could be the trigger of several autoimmune diseases such as immune thrombocytopenic purpura and systemic lupus erythematosus Objectives: To determine the frequency of H pylori in systemic lupus erythematosus patients (SLE). Methods: A cross-sectional study was done in patients who fulfilled the 2012 SLICC criteria for SLE and were willing to sign the informed consent to be subjected to endoscopic procedure. The tissue sample was analyzed by pathologist. We used mean and standard deviation to describe the data, to compare both groups Student t test was done and for continuous variables we used chi-square; the correlation analysis was performed with Results: Twenty two SLE patients were included and we chose a control group from database of endoscopic clinic with diagnosis of functional dyspepsia. Mean age of study group was 31 vs 48 year-old, 95% were women, 32% with immunosuppressant and 95% were taking antimarials. The frequency of Hp in SLE patients was 60%, dsDNA and anti-Ro autoantibodies were associated with the presence of Hp; the study group had more frequency of nodular gastritis, metaplasia and dysplasia. Seventy per cent of patients had less than 5 years of diagnosis. Conclusions: We found a high frequency of H pylori infection in patients with SLE. Metaplastic and dysplastic changes were also more prevalent in the SLE group. Our data suggest that Hp infection took place in early stages of disease. Objectives: To determine, through a systematic review and meta-analysis, the prevalence of back pain (BP) and spondyloarthritis (SpA) in the adult general population and explore the heterogeneity between studies in and out Latin America (LATAM). Methods: MEDLINE, Embase, BIREME, LILLACS and Web of Science were searched using a strategy combining key words and related database-specific subject terms to identify relevant cross-sectional studies based on COPCORD methodology published since 2006. Included articles were assessed for risk of bias and quality based on the STROBE statement. Prevalence figures for BP and SpA (European Spondyloarthropathy Study Group criteria) were analyzed according to female percentage of sampled individuals, mean age and sample size. A mixed effect model was used to obtain the combined prevalence and a meta-regression to estimate the effects of these variables. Prevalence stratified values were obtained according to its geographical location. Results: 44 out of 127 papers in English, Spanish or Portuguese were selected. Of them, 16 contained BP or SpA prevalence data. Estimates for any Spa prevalence ranged from 0,1% to 2%, with an average of 0,3% (95% CI: 0,01%>0,05%). The random-effects pooled prevalence was 0,18% (0,06%>0,36%). The prevalence of BP was 6.54% (3.8%>9.2%) with a pooled value of 5.24% (2.6%>8.7%). In both cases the heterogeneity was significant (p<0.01). No effect was associated to SpA heterogeneity, but an increase in the prevalence of BP was associated to sample size (random effect coefficient: 0,045, p=0.04). The stratified analysis did not show differences in terms of heterogeneity or prevalence for BP (Pooled prevalence for BP: 5.4%; 2.9%>8.5%, p=0.9); on the contrary, for Spa, for non-LATAM studies, the pooled proportion was significant bigger (prevalence in LATAM 0.05%, 0.01%>0.012%; non-LATAM: 0.35%, 0.09%>0.78%, p=0.03)
